492 related articles for article (PubMed ID: 26376181)
1. Patient-individualized CD8⁺ cytolytic T-cell therapy effectively combats minimal residual leukemia in immunodeficient mice.
Distler E; Albrecht J; Brunk A; Khan S; Schnürer E; Frey M; Mottok A; Jordán-Garrote AL; Brede C; Beilhack A; Mades A; Tomsitz D; Theobald M; Herr W; Hartwig UF
Int J Cancer; 2016 Mar; 138(5):1256-68. PubMed ID: 26376181
[TBL] [Abstract][Full Text] [Related]
2. Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8(+) CD62L((high)+) T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rgamma(null) mice.
Distler E; Wölfel C; Köhler S; Nonn M; Kaus N; Schnürer E; Meyer RG; Wehler TC; Huber C; Wölfel T; Hartwig UF; Herr W
Exp Hematol; 2008 Apr; 36(4):451-63. PubMed ID: 18261837
[TBL] [Abstract][Full Text] [Related]
3. HLA-DPB1 mismatch alleles represent powerful leukemia rejection antigens in CD4 T-cell immunotherapy after allogeneic stem-cell transplantation.
Herr W; Eichinger Y; Beshay J; Bloetz A; Vatter S; Mirbeth C; Distler E; Hartwig UF; Thomas S
Leukemia; 2017 Feb; 31(2):434-445. PubMed ID: 27479183
[TBL] [Abstract][Full Text] [Related]
4. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
[TBL] [Abstract][Full Text] [Related]
5. Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model.
Ma Q; Wang C; Jones D; Quintanilla KE; Li D; Wang Y; Wieder ED; Clise-Dwyer K; Alatrash G; Mj Y; Munsell MF; Lu S; Qazilbash MH; Molldrem JJ
Cytotherapy; 2010 Dec; 12(8):1056-62. PubMed ID: 20735170
[TBL] [Abstract][Full Text] [Related]
6. Mismatched human leukocyte antigen class II-restricted CD8⁺ cytotoxic T cells may mediate selective graft-versus-leukemia effects following allogeneic hematopoietic cell transplantation.
Hirosawa T; Torikai H; Yanagisawa M; Kamei M; Imahashi N; Demachi-Okamura A; Tanimoto M; Shiraishi K; Ito M; Miyamura K; Shibata K; Kikkawa F; Morishima Y; Takahashi T; Emi N; Kuzushima K; Akatsuka Y
Cancer Sci; 2011 Jul; 102(7):1281-6. PubMed ID: 21466613
[TBL] [Abstract][Full Text] [Related]
7. Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of alpha-interferon.
Faber LM; van Luxemburg-Heijs SA; Rijnbeek M; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 1996 Feb; 2(1):31-6. PubMed ID: 9078352
[TBL] [Abstract][Full Text] [Related]
8. Single-cell cloning of human, donor-derived antileukemia T-cell lines for in vitro separation of graft-versus-leukemia effect from graft-versus-host reaction.
Montagna D; Daudt L; Locatelli F; Montini E; Turin I; Lisini D; Giorgiani G; Bernardo ME; Maccario R
Cancer Res; 2006 Jul; 66(14):7310-6. PubMed ID: 16849581
[TBL] [Abstract][Full Text] [Related]
9. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.
Stevanović S; Nijmeijer BA; van Schie ML; Salvatori DC; Maas S; Griffioen M; Falkenburg JH
Biol Blood Marrow Transplant; 2013 Jun; 19(6):867-75. PubMed ID: 23500532
[TBL] [Abstract][Full Text] [Related]
10. Generation and ex vivo expansion of cytotoxic T lymphocytes directed toward different types of leukemia or myelodysplastic cells using both HLA-matched and partially matched donors.
Montagna D; Maccario R; Montini E; Tonelli R; Lisini D; Pagani S; Comoli P; Moretta A; Assirelli E; Basso S; Vitiello A; Pession A; Locatelli F
Exp Hematol; 2003 Nov; 31(11):1031-8. PubMed ID: 14585366
[TBL] [Abstract][Full Text] [Related]
11. IL-21-treated naive CD45RA+ CD8+ T cells represent a reliable source for producing leukemia-reactive cytotoxic T lymphocytes with high proliferative potential and early differentiation phenotype.
Albrecht J; Frey M; Teschner D; Carbol A; Theobald M; Herr W; Distler E
Cancer Immunol Immunother; 2011 Feb; 60(2):235-48. PubMed ID: 21046101
[TBL] [Abstract][Full Text] [Related]
12. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia.
Faber LM; van Luxemburg-Heijs SA; Willemze R; Falkenburg JH
J Exp Med; 1992 Nov; 176(5):1283-9. PubMed ID: 1402674
[TBL] [Abstract][Full Text] [Related]
13. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes.
Faber LM; van der Hoeven J; Goulmy E; Hooftman-den Otter AL; van Luxemburg-Heijs SA; Willemze R; Falkenburg JH
J Clin Invest; 1995 Aug; 96(2):877-83. PubMed ID: 7635982
[TBL] [Abstract][Full Text] [Related]
14. Possible involvement of allogeneic antigens recognised by donor-derived CD4 cytotoxic T cells in selective GVL effects after stem cell transplantation of patients with haematological malignancy.
Matsushita M; Yamazaki R; Ikeda H; Mori T; Sumimoto H; Fujita T; Okamoto S; Ikeda Y; Kawakami Y
Br J Haematol; 2006 Jan; 132(1):56-65. PubMed ID: 16371020
[TBL] [Abstract][Full Text] [Related]
15. Tissue-restricted T cell alloresponses across HLA barriers: selection and identification of leukemia-restricted CTL in HLA-mismatched stimulator-responder pairs.
Fujiwara H; Sconocchia G; Melenhorst J; Eniafe R; Nakamura R; Hensel N; Barrett AJ
Bone Marrow Transplant; 2003 Aug; 32(4):371-8. PubMed ID: 12900773
[TBL] [Abstract][Full Text] [Related]
16. The in vitro generation of multi-tumor antigen-specific cytotoxic T cell clones: Candidates for leukemia adoptive immunotherapy following allogeneic stem cell transplantation.
Mohamed YS; Bashawri LA; Vatte C; Abu-Rish EY; Cyrus C; Khalaf WS; Browning MJ
Mol Immunol; 2016 Sep; 77():79-88. PubMed ID: 27490939
[TBL] [Abstract][Full Text] [Related]
17. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
[TBL] [Abstract][Full Text] [Related]
18. Correlation between enhancement of graft-versus-leukemia effects following allogeneic bone marrow transplantation by rIL-2 and increased frequency of cytotoxic T-lymphocyte precursors in murine myeloid leukemia.
Leshem B; Vourka-Karussis U; Slavin S
Cytokines Cell Mol Ther; 2000 Sep; 6(3):141-7. PubMed ID: 11140883
[TBL] [Abstract][Full Text] [Related]
19. The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties.
Boyer MW; Vallera DA; Taylor PA; Gray GS; Katsanis E; Gorden K; Orchard PJ; Blazar BR
Blood; 1997 May; 89(9):3477-85. PubMed ID: 9129056
[TBL] [Abstract][Full Text] [Related]
20. CD34+ cord blood DC-induced antitumor lymphoid cells have efficacy in a murine xenograft model of human ALL.
Cullup H; Hsu AK; Kassianos AJ; McDonald K; Radford KJ; Rice AM
J Immunother; 2011 May; 34(4):362-71. PubMed ID: 21499125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]